Selpercatinib

The FDA granted accelerated approval to selpercatinib for the treatment of certain pediatric patients with metastatic or advanced solid tumors harboring RET alterations.

In this edition, FDA places hold on cell therapy trial after patient death, selpercatinib delivers superior outcomes and more.

Treatment with selpercatinib for advanced RET fusion-positive non-small cell lung cancer resulted in significantly longer PFS compared with platinum-based chemotherapy with or without pembrolizumab, study results showed.

MADRID — Selpercatinib improved outcomes compared with cabozantinib or vandetanib for treatment of RET-mutant medullary thyroid cancer, according to randomized phase 3 study results presented at ESMO Congress.

Selpercatinib extended PFS compared with two approved multikinase inhibitors for treatment of RET-mutant medullary thyroid cancer, according to the agent’s manufacturer.

Selpercatinib extended PFS compared with a PD-1 inhibitor-chemotherapy combination for certain adults with advanced non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

The FDA granted regular approval to selpercatinib for treatment of certain patients with non-small cell lung cancer.

In this video, David R. Gandara, MD, spoke with Healio about discussions surrounding the ADAURA trial held at the 22nd annual International Lung Cancer Congress.

Molecular oncology is a rapidly evolving field with exciting results.

Selpercatinib appeared to be effective and safe for patients with RET-altered medullary thyroid cancer and RET fusion-positive non-small cell lung cancer, according to results of two studies published in The New England Journal of Medicine.